Floatz logo

Catumaxomab

Malignant Ascites

Neovii Biotechmonoclonal_antibodyPhase 2/3Dormant
BB
68/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
58/ 100
Competitive Position
89/ 100

Competitive context

13 Active assets in the Malignant Ascites cohort.

Asset / SponsorPhaseRating
5,5'-DINITROSALICIL
Wuhan YZY Biopharma Co., Ltd.
Phase 3BB
Metformin
University of Chicago
Phase 2B
Molgramostim
Second Affiliated Hospital of Soochow University
Phase 1/2CC
Serplulimab
Second Affiliated Hospital of Soochow University
Phase 1/2CC
PD-L1 CAR-T cells
Sichuan University
Phase 1CC

View all 14 →

Same molecule, other indications

Catumaxomab is also rated in:

epithelial neoplasmDormant
B
Indicative ·
61 / 100
View asset →
fallopian tube neoplasmDormant
B
Indicative ·
57 / 100
View asset →
peritoneal neoplasmDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →